Cet appel ne nécessite pas de suivi particulier par le Département Recherche. Merci de suivre directement la procédure indiquée. Si toutefois vous souhaitez contacter le Département Recherche, écrivez à ulbkto@ulb.be (propriété intellectuelle) ou fonds.recherche@ulb.be (pour toute autre question).
ERDERA JTC 2025 - "Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation"
European Rare Diseases Research Alliance
The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with the expected impact being future use of the results to benefit patients. Projects will focus on a group of rare diseases or a single rare disease following the European definition i.e., a disease affecting not more than five in 10.000 persons in the European Community, EC associated states, and Canada. Applicants are encouraged to assemble groups of rare diseases based on relevant criteria and commonalities if this leverages added value in sharing resources or expertise.
Topics List :
Research studies on therapies using small molecules, small non-coding chemically synthesized nucleic acid-based therapies, repurposed drugs or biologicals (e.g., antibodies or proteins such as enzymes, immune modulators or growth factors etc.). Proposals must cover at least one of the following areas:
1. development of novel therapies in a preclinical setting through cell, organoid and animal model studies, molecule screening or use of in silico or artificial intelligence models
2. development of predictive and pharmacodynamics biomarkers correlated to the efficiency of the therapy in a preclinical setting that could serve as surrogate endpoints
3. replication of pre-clinical studies in an independent lab to increase validity of exploratory findings
4. pre-clinical proof of concept studies for evidence of pharmacological activity in vitro and in vivo, pharmaco-kinetics and pharmaco-dynamics of the drug and first toxicology and safety data
5. studies to support readiness for initiating clinical trial authorization conforming to regulatory requirements
Translatability into humans should be the key focus of the project, and applicants should demonstrate access to relevant scientific or regulatory expertise (e.g., through innovation task forces or competent national authorities).
Financement
The maximum duration of the project is three years.
Double funding of research projects is not permitted. The JCS and national/regional funding organisations may perform cross-checks of submissions against other funding initiatives managed by the same organisations (both national/regional calls and Joint Transnational Calls, e.g. NEURON, JPND, or European Partnerships such as ERA4Health, EP PerMed, THCS etc.). Partners may not apply for funding for the same research activities in different calls. In addition, there can be no double funding for activities already funded by EC H2020 and Horizon Europe calls.
Consortia of projects funded in previous Joint Transnational Calls of the EJP RD can apply for funding for an extension of their cooperation in a new project, but only for new research activities not yet funded under the previous Call. These consortia must clearly demonstrate the success of the past/current project and innovative scientific aims for their future collaboration. Their applications will compete with applications for new research projects.
Pour postuler
Research consortia who intend to submit a transnational project proposal should register as soon as possible via the electronic proposal system: https://funding.erdera.org
There will be a two-stage submission procedure for joint applications: a pre- and full proposal stage. In both cases, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal and must be submitted by the coordinator only to the JCS via the electronic submission system. Proposals must be prepared using the templates provided in the electronic system. Proposals not conforming to template instructions will be rejected.
Full proposals will be accepted only from those applicants who were explicitly invited by the JCS to submit them. composition of the consortia, objectives of the project, or requested budget can only be applied with a detailed justification provided to the JCS for consideration by the CSC. Potential justifications may include advice gathered on the feasibility of the project indicating the need for additional expertise and/or resources, or the addition of partner(s) through the widening scheme. However, the national/regional regulations on eligible partners and budget caps will still apply and the budget change needs to be pre-approved by relevant national/regional funding organisation(s).
Further information on how to submit pre-proposals and full proposals electronically (including “Guidelines for Applicants” and submission templates) is available at the ERDERA website.
Requis d'admission
Only transnational projects will be funded. Each consortium submitting a proposal must involve four to six eligible principal investigator partners (referred to as partners below) from at least four different participating countries (see list in section 2). One of these four to six partners must be an Early Career Researcher (ECR; see section 5.6). In specific cases this number of consortium partners can be increased to eight partners (see below). No more than two eligible partners from the same country can be present in each consortium; further national/regional limits may apply, see “Guidelines for Applicants”. Patient advocacy organisations (PAOs) requesting funding do not count toward the total.
Zones géographiques
Les zones géographiques n'ont pas encore été spécifiées.